CRISPR Therapeutics benefits from Casgevy’s approval and a deep pipeline, despite early rollout hurdles and cost challenges.

Fyodor Urnov and Kiran Musunuru advocate for streamlined CRISPR treatments for rare genetic diseases, partnering with Danaher ...

The University of Bayreuth's Biomaterials research group has, for the first time, successfully applied the CRISPR-Cas9 ...

CRISPR Therapeutics faces challenges with a 20% stock drop, slow Casgevy commercialization, and regulatory hurdles. Read more ...

The US Food and Drug Administration has approved a type of CRISPR gene-edited pig for human consumption.

The cost of sequencing DNA has dropped dramatically, and with technologies like CRISPR, gene editing is becoming more precise ...